| |
Join our trial design experts on Thursday, May 8 for an insightful webinar on the optimal use cases of master protocols in clinical trials. Register now. .png)
|
|
Today’s Big NewsApr 30, 2025 |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now. 
|
|
| By Nick Paul Taylor Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus Therapeutics for a rare renal disease drug that is set to enter phase 3 in the third quarter. |
|
|
|
By Nick Paul Taylor An investor is ratcheting up the pressure on Acelyrin to pull out of a planned merger with Alumis, setting out its case for voting against a deal it argues is worse for shareholders than liquidating the biotech. |
By Nick Paul Taylor Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech has set out plans to reduce its workforce by 20% and prioritize its clinical Duchenne muscular dystrophy candidates and key preclinical programs. |
By Gabrielle Masson The affected Cambridge site is Ono’s U.S. headquarters and one of the company's two locations in the country, with the other in San Francisco. |
|
Get a head start on your IND submission. Lonza's rapid tox offering cuts toxicology material delivery times by up to 50%, overcoming critical bottlenecks. Learn how to streamline your development and hear about our new exciting offering for bispecifics in this webinar. .png)
|
|
By Gabrielle Masson Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after looking to partner off its sole clinical-stage asset to no avail this winter. |
By Gabrielle Masson An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been delayed—again—this time, with no new decision date given. |
By Kevin Dunleavy AstraZeneca has come up short in another phase 3 trial of AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. |
By Zoey Becker The company is going up against Pfizer's popular Vyndaqel franchise in the ATTR-CM field and has so far tallied 2,072 prescriptions since launching Attruby in December. |
By Conor Hale The MJFF has worked with Verily for years to assemble public data exploring the relationships between Parkinson's disease, genetics, the immune system and metabolism. |
By Eric Sagonowsky Authorities say Gilead paid honoraria payments, meals and travel expenses to induce participants at HIV educational speaker programs to prescribe its HIV drugs. The company is paying more than $200 million to resolve the allegations. |
Fierce podcasts Don’t miss an episode |
| Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Available On-Demand Commissioning and qualification (C&Q) is vital within pharma manufacturing. View this valuable webinar on-demand to explore key strategies for effective management of systems, equipment and processes to ensure product safety, regulatory compliance, operational efficiency and overall quality assurance. 
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
